Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;28(3):371-391.
doi: 10.2174/0113862073303342240409060918.

Therapeutic Expedition of Luteolin against Brain-related Disorders: An Updated Review

Affiliations
Review

Therapeutic Expedition of Luteolin against Brain-related Disorders: An Updated Review

Niraj Kumar Singh et al. Comb Chem High Throughput Screen. 2025.

Abstract

Brain-related disorders include neuroinflammation, neurodegenerative disorders, and demyelination, which ultimately affect the quality of life of patients. Currently, brain-related disorders represent the most challenging health problem worldwide due to complex pathogenesis and limited availability of drugs for their management. Further, the available pharmacotherapy accompanies serious side effects, therefore, much attention has been directed toward the development of alternative therapy derived from natural sources to treat such disorders. Recently, flavonoids, natural phytochemicals, have been reported as a treatment option for preventing brain aging and disorders related to this. Among these flavonoids, dietary luteolin, a flavone, is found in many plant products such as broccoli, chamomile tea, and honeysuckle bloom having several pharmacological properties including neuroprotective activities. Therefore, the objective of this paper is to compile the available literature regarding the neuroprotective potential of luteolin and its mechanism of action. Luteolin exerts notable anti-inflammatory, antioxidant, and antiapoptotic activity suggesting its therapeutic efficacy in different neurological disorders. Numerous in-vivo and in-vitro experiments have revealed that luteolin exhibits neuroprotective potential via up-regulating the ER/ERK, PI3AKT, Nrf2 pathways and down-regulating the MAPK/JAK2STAT and NFκB pathways. Taking into account of available facts regarding the neuroprotective efficacy of luteolin, the current study highlights the beneficial effects of luteolin for the prevention, management, and treatment of different neurological disorders. Thus, luteolin can be considered an alternative for the development of new pharmacophores against various brain-related disorders.

Keywords: Luteolin; alzheimer’s disease; brain-related disorders; flavonoids; neuroinflammation; parkinson’s disease..

PubMed Disclaimer

Similar articles

Cited by

References

    1. Zahiruddin S.; Basist P.; Parveen A.; Parveen R.; Khan W.; Gaurav; Ahmad, S. Ashwagandha in brain disorders: A review of recent developments. J Ethnopharmacol 2020,257,112876 - DOI - PubMed
    1. Harro J.; Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine. Int Rev Neurobiol 2015,120,179-204 - DOI - PubMed
    1. Kou Y.; Zhao H.; Cui D.; Han H.; Tong Z.; Formaldehyde toxicity in age-related neurological dementia. Ageing Res Rev 2022,73,101512 - DOI - PubMed
    1. Balkrishna A.; Misra L.; Chemo-botanical and neurological accounts of some ayurvedic plants useful in mental health. Nat Prod J 2018,8(1),14-31 - DOI
    1. Sarris J.; Ravindran A.; Yatham L.N.; Marx W.; Rucklidge J.J.; McIntyre R.S.; Akhondzadeh S.; Benedetti F.; Caneo C.; Cramer H.; Cribb L.; de Manincor M.; Dean O.; Deslandes A.C.; Freeman M.P.; Gangadhar B.; Harvey B.H.; Kasper S.; Lake J.; Lopresti A.; Lu L.; Metri N.J.; Mischoulon D.; Ng C.H.; Nishi D.; Rahimi R.; Seedat S.; Sinclair J.; Su K.P.; Zhang Z.J.; Berk M.; Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT). Taskforce World J Biol Psychiatry 2022,23(6),424-455 - DOI - PubMed

MeSH terms

LinkOut - more resources